PADMSOT_PINCT06966297
MSOT_PI Analysis of Revascularization Procedure Using Optoacoustic Imaging
An observational study of PAD and Vascular Diseases, run by University Hospital Erlangen at 1 site in Germany.
Trial summary
The aim of the proposed study is to analyse the improvement of the calf muscle perfusion of patients with PAD Fontaine stage II and critical limb threatheaning ischemia (CLTI) after endovascular and surgical revascularization procedures using multispectral optoacoustic tomography (MSOT) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PAD, Vascular Diseases
- What is being tested?
- Multispectral optoacoustic tomography
- How many people
- 40 participants
- Where
- 1 siteGermany
- Study dates
- 1 Mar 2024to 1 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: 40 patients diagnosed with PAD were recruited for the study. Patients were included if they were scheduled for revascularization, either through endovascular therapy or an open surgical procedure.
Who may be able to join
- Diagnosis of PAD confirmed by clinical examination and ABI (ABI ≤ 0.90)
- Planned for elective revascularization therapy
- Able to provide informed consent
- PAD stages II-IV Fontaine
- Age of > 18 years
Who cannot join
- Severe comorbid conditions
- Non-PAD related walking impairments (e.g., neurological disorders)
- Inability to comply with study protocols
- PAD stage I
- Age of < 18 years
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of Calf Muscle Perfusion in Patients With Peripheral Arterial Disease After Revascularization Procedure Using Multispectral Optoacoustic Tomography
The aim of the proposed study is to analyse the improvement of the calf muscle perfusion of patients with PAD Fontaine stage II and critical limb threatheaning ischemia (CLTI) after endovascular and surgical revascularization procedures using multispectral optoacoustic tomography (MSOT)
Read the detailed description
Since 2021, the University Hospital Erlangen (department of pediatrics) disposes of a CE-certified multispectral optoacoustic tomograph (MSOT). Similar to sonography, the MSOT technology allows for non-invasive, quantitative imaging of the composition and also oxygenation of target tissues such as muscle.
Just like with conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via flashes of laser light. This leads to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same examination unit that sends in the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
These parameters have already been successfully measured, validated and reproduced in preliminary studies. Furthermore, a first internal study (MSOT_PAD, NCT04641091) confirmed the hypothesis that data collected via MSOT can be used for PAD diagnostics. The derived concentration of oxygenated hemoglobin (HbO2) proved to be the most suitable measurement parameter. Correlations could be established between the measured HbO2 concentration and the radiological and clinical severity of the PAD.
These results are very promising in terms of using the MSOT technique in diagnosis and monitoring of PAD. In particular, the establishment of this method would be of great value for the examination of PAD patients in whom, due to previous illness such as severe chronic renal insufficiency or diabetes mellitus, the measurement of the ABI or the CCDS examination do not provide valid results due to progressive stiffening of the vascular wall (Mönckeberg mediasclerosis). This also applies to patients who, due to previous illness or operations, cannot perform treadmill exercise to determine the absolute walking distance. With MSOT, an objectifiable measurement method for non-invasive monitoring of the actual target organ muscle could be established for the first time, which would be especially helpful in the mentioned patient groups. Up until now there are no non-invasive measurement methods other than MSOT that can make transcutaneous statements about muscle perfusion.
In the previous study (MSOT_PAD, NCT04641091), differentiability of clinical PAD stages improved after a standardized exercise of a walking distance of 150 meters, with patients in the stage of intermittent claudication (IC, Fontaine stage II) being harder to differentiate compared to patients in stage III and IV. For diagnostic methods that address macrocirculation (especially ABI and FKDS), provocation tests are routinely used in PAD diagnostics and already standardized. As a rule, patients with PAD are stressed up to their personal stress limit (ischemia pain). The respective examination is then repeated afterwards. This increases the ability to differentiate macrocirculatory variables, especially for minor pathologies. We assume that this also applies to the hemoglobin concentrations (at the microcirculation level), even though up until now there are no measurement methods for this.
The MSOT technique, with its non-invasive, direct measurement of muscle perfusion, could prove to be particularly helpful for IC patients in terms of early diagnosis and follow-up. Where previously conservative therapy monitoring was based mainly on anamnesis, the MSOT technique could enable objective control and evaluation of the conservative and interventional/surgical treatment approaches. In the future this might entail further comparative outcome studies which might then even result in indication changes for the various therapeutic measures - which would improve the overall care situation of PAD patients.
In a further cross-sectional study, a large group of IC patients was examined using a more suited exercising of the calf muscle namely repeated heel raises until the occurrence of claudication pain. With this improved protocol, sensitivity and specificity of the procedure could be improved compared to the preliminary study.
With the help of this improved protocol we now want to examine whether and how the improved blood flow situation translates to the measured MSOT parameters. MSOT-scans of patients with PAD fontaine stage II and critical limb threathening ischemia will be conducted before and after endovascular or surgical revascularization procedure. . This comparison of muscle perfusion before and after revascularization is the obvious next step in this area of research. The study could help validate the therapeutic succes of said interventions as the currently available non-invasive diagnostics still pose limitations to objectively quantify the success of revascularization procedures.
As an additional target variable, the PAD-specific quality of life will be recorded via the VASCUQOL-6 questionnaire.
- Conditions
- PAD, Vascular Diseases
- Being tested
- Multispectral optoacoustic tomography
- Keywords
- PAD, Optoacoustic Imaging
- Medical subject headings
- Vascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multispectral optoacoustic tomographyDiagnostic test
Measurement of calf muscle Perfusion via Multispectral optoacoustic Tomography
| Study group | Role | What they receive |
|---|---|---|
| PAD Fontaine stage II endo | Patients in PAD Stage II receiving endovascular revascularization procedures | |
| PAD Fontaine stage II open | Patients in PAD Stage II receiving open surgical revascularization procedures Receives: Diagnostic Test: Multispectral optoacoustic tomography | |
| PAD CLTI endo | Patients in PAD-CLTI (Chronic limb threatening ischemia) receiving endovascular revascularization procedures Receives: Diagnostic Test: Multispectral optoacoustic tomography | |
| PAD CLTI open | Patients in PAD PAD-CLTI (Chronic limb threatening ischemia) receiving open surgical revascularization procedures Receives: Diagnostic Test: Multispectral optoacoustic tomography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hemoglobin associated parameters measured via Multispectral optoacoustic Tomography
Measured: 1 Hour
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2025
- Study start1 Mar 2024
- Primary completion10 Feb 2025
- Study completion1 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for PADStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Erlangen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ulrich Rother, University Hospital Erlangen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06966297
- Sponsor's protocol ID
- MSOT_PI
- Acronym
- MSOT_PI
- Status last verified
- May 2025
- First submitted
- 2 May 2025
- Last updated
- 15 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Larsen ASF, Reiersen AT, Jacobsen MB, Klow NE, Nordanstig J, Morgan M, Wesche J. Validation of the Vascular quality of life questionnaire - 6 for clinical use in patients with lower limb peripheral arterial disease. Health Qual Life Outcomes. 2017 Sep 22;15(1):184. doi: 10.1186/s12955-017-0760-3.
PubMed 28938901Lawall, H., P. Huppert, and G. Rümenapf. "S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit." Deutsche Gesellschaft für Angiologie und Deutsche Gesellschaft für Gefäßmedizin 30 (2015).
Lanzer, P. (2018). Primary media sclerosis Mönckeberg: Diagnostic criteria. Cor et Vasa, 60(2), e205-e208.
Alpert JS, Larsen OA, Lassen NA. Exercise and intermittent claudication. Blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation. 1969 Mar;39(3):353-9. doi: 10.1161/01.cir.39.3.353. No abstract available.
PubMed 4885945Karlas A, Masthoff M, Kallmayer M, Helfen A, Bariotakis M, Fasoula NA, Schafers M, Seidensticker M, Eckstein HH, Ntziachristos V, Wildgruber M. Multispectral optoacoustic tomography of peripheral arterial disease based on muscle hemoglobin gradients-a pilot clinical study. Ann Transl Med. 2021 Jan;9(1):36. doi: 10.21037/atm-20-3321.
PubMed 33553329
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Calf Muscle Perfusion in Patients With Peripheral Arterial Disease After Revascularization Procedure Using Multispectral Optoacoustic Tomography
- ClinicalTrials.gov ID
- NCT06966297
- Acronym / sponsor ID
- MSOT_PI / MSOT_PI
- Conditions
- PAD, Vascular Diseases
- Keywords
- PAD, Optoacoustic Imaging
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University Hospital ErlangenUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 10 Feb 2025 (actual)
- Study completion
- 1 Mar 2025 (actual)
- First posted
- 11 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the proposed study is to analyse the improvement of the calf muscle perfusion of patients with PAD Fontaine stage II and critical limb threatheaning ischemia (CLTI) after endovascular and surgical revascularization procedures using multispectral optoacoustic tomography (MSOT)
Detailed description
Since 2021, the University Hospital Erlangen (department of pediatrics) disposes of a CE-certified multispectral optoacoustic tomograph (MSOT). Similar to sonography, the MSOT technology allows for non-invasive, quantitative imaging of the composition and also oxygenation of target tissues such as muscle.
Just like with conventional sonography, the MSOT transducer head is placed on the skin of the examined person above the target organ. But instead of sound waves, energy is applied to the tissue via flashes of laser light. This leads to constant changes of minimal expansions and contractions (thermoelastic expansion) of different tissue components or molecules. The same examination unit that sends in the laser flashes can also detect the emitted ultrasound waves. In the newly configured device (Acuity Echo, iThera Medical GmbH, Munich, CE-certified), an extended spectrum of laser light can be used, enabling among others the derivation of values corresponding to hemoglobin and its oxygenation levels. As hemoglobin concentration and oxygenation status are markers for perfusion, MSOT-based imaging of these parameters could be a highly sensitive and reliable method to analyze muscle perfusion.
These parameters have already been successfully measured, validated and reproduced in preliminary studies. Furthermore, a first internal study (MSOT_PAD, NCT04641091) confirmed the hypothesis that data collected via MSOT can be used for PAD diagnostics. The derived concentration of oxygenated hemoglobin (HbO2) proved to be the most suitable measurement parameter. Correlations could be established between the measured HbO2 concentration and the radiological and clinical severity of the PAD.
These results are very promising in terms of using the MSOT technique in diagnosis and monitoring of PAD. In particular, the establishment of this method would be of great value for the examination of PAD patients in whom, due to previous illness such as severe chronic renal insufficiency or diabetes mellitus, the measurement of the ABI or the CCDS examination do not provide valid results due to progressive stiffening of the vascular wall (Mönckeberg mediasclerosis). This also applies to patients who, due to previous illness or operations, cannot perform treadmill exercise to determine the absolute walking distance. With MSOT, an objectifiable measurement method for non-invasive monitoring of the actual target organ muscle could be established for the first time, which would be especially helpful in the mentioned patient groups. Up until now there are no non-invasive measurement methods other than MSOT that can make transcutaneous statements about muscle perfusion.
In the previous study (MSOT_PAD, NCT04641091), differentiability of clinical PAD stages improved after a standardized exercise of a walking distance of 150 meters, with patients in the stage of intermittent claudication (IC, Fontaine stage II) being harder to differentiate compared to patients in stage III and IV. For diagnostic methods that address macrocirculation (especially ABI and FKDS), provocation tests are routinely used in PAD diagnostics and already standardized. As a rule, patients with PAD are stressed up to their personal stress limit (ischemia pain). The respective examination is then repeated afterwards. This increases the ability to differentiate macrocirculatory variables, especially for minor pathologies. We assume that this also applies to the hemoglobin concentrations (at the microcirculation level), even though up until now there are no measurement methods for this.
The MSOT technique, with its non-invasive, direct measurement of muscle perfusion, could prove to be particularly helpful for IC patients in terms of early diagnosis and follow-up. Where previously conservative therapy monitoring was based mainly on anamnesis, the MSOT technique could enable objective control and evaluation of the conservative and interventional/surgical treatment approaches. In the future this might entail further comparative outcome studies which might then even result in indication changes for the various therapeutic measures - which would improve the overall care situation of PAD patients.
In a further cross-sectional study, a large group of IC patients was examined using a more suited exercising of the calf muscle namely repeated heel raises until the occurrence of claudication pain. With this improved protocol, sensitivity and specificity of the procedure could be improved compared to the preliminary study.
With the help of this improved protocol we now want to examine whether and how the improved blood flow situation translates to the measured MSOT parameters. MSOT-scans of patients with PAD fontaine stage II and critical limb threathening ischemia will be conducted before and after endovascular or surgical revascularization procedure. . This comparison of muscle perfusion before and after revascularization is the obvious next step in this area of research. The study could help validate the therapeutic succes of said interventions as the currently available non-invasive diagnostics still pose limitations to objectively quantify the success of revascularization procedures.
As an additional target variable, the PAD-specific quality of life will be recorded via the VASCUQOL-6 questionnaire.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| PAD Fontaine stage II endo | – | –Patients in PAD Stage II receiving endovascular revascularization procedures |
| PAD Fontaine stage II open | – | Diagnostic Test: Multispectral optoacoustic tomographyPatients in PAD Stage II receiving open surgical revascularization procedures |
| PAD CLTI endo | – | Diagnostic Test: Multispectral optoacoustic tomographyPatients in PAD-CLTI (Chronic limb threatening ischemia) receiving endovascular revascularization procedures |
| PAD CLTI open | – | Diagnostic Test: Multispectral optoacoustic tomographyPatients in PAD PAD-CLTI (Chronic limb threatening ischemia) receiving open surgical revascularization procedures |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- 40 patients diagnosed with PAD were recruited for the study. Patients were included if they were scheduled for revascularization, either through endovascular therapy or an open surgical procedure.
Key inclusion criteria (5 listed)
- Diagnosis of PAD confirmed by clinical examination and ABI (ABI ≤ 0.90)
- Planned for elective revascularization therapy
- Able to provide informed consent
- PAD stages II-IV Fontaine
- Age of > 18 years
Key exclusion criteria (5 listed)
- Severe comorbid conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multispectral optoacoustic tomographyMeasurement of calf muscle Perfusion via Multispectral optoacoustic Tomography | Diagnostic test | PAD CLTI endo, PAD CLTI open, PAD Fontaine stage II open |
Primary outcome
Hemoglobin associated parameters measured via Multispectral optoacoustic Tomography
Time frame: 1 Hour
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2025.
- Background: PubMed 28938901Larsen ASF, Reiersen AT, Jacobsen MB, Klow NE, Nordanstig J, Morgan M, Wesche J. Validation of the Vascular quality of life questionnaire - 6 for clinical use in patients with lower limb peripheral arterial disease. Health Qual Life Outcomes. 2017 Sep 22;15(1):184. doi: 10.1186/s12955-017-0760-3.
- BackgroundLawall, H., P. Huppert, and G. Rümenapf. "S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit." Deutsche Gesellschaft für Angiologie und Deutsche Gesellschaft für Gefäßmedizin 30 (2015).
- BackgroundLanzer, P. (2018). Primary media sclerosis Mönckeberg: Diagnostic criteria. Cor et Vasa, 60(2), e205-e208.
- Background: PubMed 4885945Alpert JS, Larsen OA, Lassen NA. Exercise and intermittent claudication. Blood flow in the calf muscle during walking studied by the xenon-133 clearance method. Circulation. 1969 Mar;39(3):353-9. doi: 10.1161/01.cir.39.3.353. No abstract available.
- Background: PubMed 33553329Karlas A, Masthoff M, Kallmayer M, Helfen A, Bariotakis M, Fasoula NA, Schafers M, Seidensticker M, Eckstein HH, Ntziachristos V, Wildgruber M. Multispectral optoacoustic tomography of peripheral arterial disease based on muscle hemoglobin gradients-a pilot clinical study. Ann Transl Med. 2021 Jan;9(1):36. doi: 10.21037/atm-20-3321.
- Individual participant dataSharing planned: No
Related trials for PAD
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Not yet recruiting
Daily Stretching to Improve Walking in Older Patients With Peripheral Artery Disease: The STRETCH PAD Study
Peripheral Artery Disease (PAD), Intermittent Claudication
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of PAD and Vascular Diseases, run by University Hospital Erlangen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hemoglobin associated parameters measured via Multispectral optoacoustic Tomography (time frame: 1 Hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06966297, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.